LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

Search

Charles River Laboratories International Inc

Chiusa

SettoreSettore sanitario

178.46 1.8

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

168.51

Massimo

179.56

Metriche Chiave

By Trading Economics

Entrata

-332M

-277M

Vendite

-11M

994M

EPS

2.43

Margine di Profitto

-27.816

Dipendenti

18,300

EBITDA

730K

198M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+16.44% upside

Dividendi

By Dow Jones

Utili prossimi

6 mag 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

107M

8B

Apertura precedente

176.66

Chiusura precedente

178.46

Notizie sul Sentiment di mercato

By Acuity

25%

75%

50 / 352 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bullish Evidence

Charles River Laboratories International Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

26 feb 2026, 22:04 UTC

Utili

Coles 1st Half Net Profit Falls 11% on Worker Remediation Costs

26 feb 2026, 23:55 UTC

Discorsi di Mercato

Gold Edges Higher as Traders Digest U.S.-Iran Talks -- Market Talk

26 feb 2026, 23:40 UTC

Acquisizioni, Fusioni, Takeovers

Paramount Wins Bidding War for Warner Discovery After Netflix Drops Out -- Update

26 feb 2026, 23:37 UTC

Discorsi di Mercato

Japanese Stocks May Fall, Tracking Wall Street's Decline -- Market Talk

26 feb 2026, 23:32 UTC

Utili

Why Nvidia's Huge Numbers Don't Settle the Latest AI Fears -- Heard on the Street -- WSJ

26 feb 2026, 23:19 UTC

Acquisizioni, Fusioni, Takeovers

Paramount Wins Bidding War for Warner Discovery After Netflix Drops Out -- WSJ

26 feb 2026, 23:18 UTC

Acquisizioni, Fusioni, Takeovers

Paramount Wins Bidding War for Warner Discovery After Netflix Drops Out -- WSJ

26 feb 2026, 23:12 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Global Equities Roundup: Market Talk

26 feb 2026, 23:12 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Netflix Gives Up in Bidding War Over Warner -- Market Talk

26 feb 2026, 23:01 UTC

Acquisizioni, Fusioni, Takeovers

Netflix Declines to Match Paramount's Offer for Warner Bros. -- Barrons.com

26 feb 2026, 23:00 UTC

Acquisizioni, Fusioni, Takeovers

Netflix Declines to Match Paramount's Offer for Warner Bros. -- Barrons.com

26 feb 2026, 23:00 UTC

Acquisizioni, Fusioni, Takeovers

Warner Discovery Says Paramount's Latest Bid Is Superior to Netflix Deal -- Update

26 feb 2026, 22:55 UTC

Acquisizioni, Fusioni, Takeovers

Netflix Declines to Match Paramount's Offer for Warner Bros. -- Barrons.com

26 feb 2026, 22:43 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

26 feb 2026, 22:43 UTC

Discorsi di Mercato

RBA Hike In March Is Being Underpriced -- Market Talk

26 feb 2026, 22:33 UTC

Acquisizioni, Fusioni, Takeovers

Netflix Has 4 Days to Make a New Offer for Warner Bros. The Bidding War Continues. -- Barrons.com

26 feb 2026, 22:20 UTC

Acquisizioni, Fusioni, Takeovers

Warner Discovery Says Paramount's Latest Bid Is Superior to Netflix Deal -- Update

26 feb 2026, 22:13 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Bidding War Over Warner Bros. Set to Continue -- Market Talk

26 feb 2026, 21:59 UTC

Utili

D-Wave Quantum Stock Rises on Earnings. Why a Revenue Miss Doesn't Seem to Matter. -- Barrons.com

26 feb 2026, 21:58 UTC

Acquisizioni, Fusioni, Takeovers

Netflix Has 4 Days to Make a New Offer for Warner Bros. The Bidding War Continues. -- Barrons.com

26 feb 2026, 21:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

26 feb 2026, 21:49 UTC

Utili

Coles 1H Net Profit Falls 11% on Worker Remediation Costs

26 feb 2026, 21:45 UTC

Utili

Coles Expects One-Off Costs of Around A$7 Million in 1H to Complete Simplification Process

26 feb 2026, 21:44 UTC

Utili

Coles Says Liquor Sales Fell 2.5% in First Seven Weeks of 3Q

26 feb 2026, 21:44 UTC

Utili

Coles Expects Market to Remain Highly Competitive

26 feb 2026, 21:44 UTC

Utili

Coles Says Supermarket Customers Remain Value Oriented

26 feb 2026, 21:43 UTC

Utili

Coles Says Supermarket Sales Revenue Up 5.3% in First Seven Weeks of 3Q When Tobacco Excluded

26 feb 2026, 21:43 UTC

Utili

Coles Says Supermarket Sales Revenue Up 3.7% in First Seven Weeks of 3Q

26 feb 2026, 21:42 UTC

Acquisizioni, Fusioni, Takeovers

Warner Discovery Says Paramount's Latest Bid Is Superior to Netflix Deal -- WSJ

26 feb 2026, 21:41 UTC

Utili
Acquisizioni, Fusioni, Takeovers

Warner Bros. Earnings Report Falls Short. What It Means for the Netflix Takeover Saga. -- Barrons.com

Confronto tra pari

Modifica del prezzo

Charles River Laboratories International Inc Previsione

Obiettivo di Prezzo

By TipRanks

16.44% in crescita

Previsioni per 12 mesi

Media 204.3 USD  16.44%

Alto 265 USD

Basso 175 USD

Basato su 12 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Charles River Laboratories International Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

12 ratings

8

Acquista

4

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

117.16 / 144.77Supporto e resistenza

A breve termine

Strong Bullish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

50 / 352 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste molto forti

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat